Charlotte Vergnenègre

Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

Marie Kostine, Eleonora Mauric, Alice Tison et al. · European Journal of Cancer · 2021 · 93 citations · Full text

Medicine, Oncology, Pharmacology +15

Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers

Matthieu Dusselier, Élise Deluche, Nellie Delacourt et al. · PLoS ONE · 2019 · 57 citations · Full text

Medicine, Immunology, Oncology +16

Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study

Luc Héraudet, Tara Delon, Rémi Veillon et al. · Thoracic Cancer · 2022 · 19 citations · Full text

Medicine, Oncology, Pharmacology +17

A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer

Clara Faubry, Maxime Faure, Anne‐Claire Toublanc et al. · Frontiers in Cardiovascular Medicine · 2022 · 16 citations · Full text

Medicine, Cardiology, Oncology +15

Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis

Céline Eldani, Marie Kostine, Maxime Faure et al. · Frontiers in Oncology · 2024 · 16 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17